Jundishapur J Nat Pharm Prod. 2026 August; 21(3): e173988 https://doi.org/10.5812/jjnpp-173988

Published Online: 2026 August 5 **Editorial**

Innovations in Nutraceuticals: Bridging Natural Products, Nanotechnology, and Precision Medicine

Eskandar Moghimipour [1, 2, *]

[1] Medicinal Plants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
[2] Department of Drug and Food Control, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

[*] ***Corresponding Author:*** Medicinal Plants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: moghimipour@yahoo.com

Received: 1 August, 2026; **Accepted:** 1 August, 2026

Keywords: Nutraceuticals, Nanomedicine, Precision Nutrition

1.1. Body Text

The twenty-first century has witnessed a remarkable shift in healthcare, moving beyond the traditional focus on treating disease toward preventing illness, promoting long-term health, and delivering more personalized care. In this context, nutraceuticals have attracted increasing attention as a rapidly evolving field integrating natural products, pharmaceutical sciences, nutrition, and biotechnology. A growing body of research indicates that many food-derived bioactive compounds possess important pharmacological activities that may help prevent, delay, or manage the progression of chronic diseases. Despite the rapid growth of the global nutraceutical market, translating these promising compounds into evidence-based healthcare solutions remains a significant scientific challenge. Looking ahead, the integration of natural products with advanced pharmaceutical technologies, nanotechnology, artificial intelligence, and precision medicine is expected to play an essential role in shaping the next generation of nutraceutical research and development.

Natural products have formed the foundation of traditional medicine for centuries and continue to play a vital role in modern healthcare. A wide variety of natural sources, including medicinal plants, marine organisms, fungi, algae, probiotics, and bee products, are rich in biologically active compounds such as polyphenols, flavonoids, terpenoids, alkaloids, carotenoids, phytosterols, peptides, and essential fatty acids. Extensive experimental research has demonstrated that these bioactive molecules possess diverse pharmacological properties, including antioxidant, anti-inflammatory, antimicrobial, anticancer, neuroprotective, cardioprotective, and immunomodulatory activities (1-3). Despite these promising biological effects, translation into clinical practice has remained limited. Many phytochemicals exhibit poor aqueous solubility, chemical and metabolic instability, limited gastrointestinal absorption, extensive first-pass metabolism, and inadequate tissue distribution, all of which substantially reduce bioavailability and therapeutic efficacy.

Recent advances in pharmaceutical nanotechnology have begun to address many of these limitations, creating new opportunities to develop more effective nutraceuticals. Nanocarrier-based delivery systems, including liposomes, phytosomes, microemulsions, nanoemulsions, polymeric nanoparticles, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), dendrimers, and self-emulsifying drug delivery systems (SEDDS), have shown considerable promise in enhancing the pharmacokinetic and pharmacodynamic performance of natural bioactive compounds. By improving physicochemical stability, protecting sensitive molecules from degradation, enhancing intestinal permeability and absorption, prolonging systemic circulation, and facilitating targeted delivery, these technologies have significantly expanded the therapeutic potential of many natural compounds previously constrained by unfavorable physicochemical properties (2, 4, 5). Consequently, nanotechnology has become a key enabling platform for translating promising nutraceuticals from laboratory research into clinically relevant interventions.

How to Cite: Moghimipour E. Innovations in Nutraceuticals: Bridging Natural Products, Nanotechnology, and Precision Medicine. Jundishapur J Nat Pharm Prod. 2026;21(3):e173988. doi: https://doi.org/10.5812/jjnpp-173988

Among the various nanotechnology-based delivery platforms, lipid-based nanocarriers have attracted particular interest because of their excellent biocompatibility, biodegradability, safety profile, and potential for large-scale pharmaceutical manufacturing. Liposomal formulations have been widely investigated to improve the delivery of bioactive compounds such as curcuma, quercetin, resveratrol, epigallocatechin gallate (EGCG), fish oil, and numerous botanical extracts, resulting in enhanced solubility, stability, bioavailability, and therapeutic efficacy (6). Likewise, SLNs and NLCs have shown considerable promise for the topical, oral, pulmonary, and ocular delivery of natural compounds by improving permeability, protecting labile molecules from degradation, and enabling controlled or sustained drug release. These advances demonstrate how novel pharmaceutical formulations can overcome many intrinsic limitations of natural bioactive compounds, effectively bridging the gap between traditional herbal medicine and modern evidence-based therapeutics.

Beyond advances in formulation science, precision medicine is transforming how nutraceuticals are developed and applied. Conventional dietary recommendations are largely based on the assumption that individuals respond similarly to nutritional interventions. However, growing evidence indicates that genetic variation, epigenetic regulation, gut microbiome composition, environmental exposures, and lifestyle factors contribute to substantial interindividual differences in responses to bioactive food compounds. Consequently, precision nutrition has emerged as an approach that aims to personalize dietary recommendations and nutraceutical interventions according to an individual's unique biological characteristics. This personalized approach has the potential to maximize therapeutic efficacy, minimize unnecessary supplementation, and support more cost-effective healthcare (7, 8).

Artificial intelligence (AI) is further accelerating innovation across the nutraceutical development pipeline. By integrating machine learning, big data analytics, and computational modeling, AI enables the rapid analysis of large phytochemical databases, the identification of novel bioactive compounds, the prediction of molecular targets and biological pathways, the optimization of extraction processes, and the rational design of advanced formulations. AI-based computational models are increasingly used to predict bioavailability, physicochemical stability, molecular interactions, and potential synergistic effects among bioactive compounds, thereby enabling optimization of nutraceutical formulations before experimental validation (9). In addition, AI-assisted analysis of clinical, multiomics, and real-world health data facilitates patient stratification and supports the development of personalized nutraceutical strategies. Collectively, these computational approaches are expected to shorten product-development timelines, reduce research and development costs, and improve the likelihood of successful clinical translation.

Another rapidly evolving area of nutraceutical research is the development of microbiome-targeted interventions. The human gut microbiome is now recognized as a central regulator of metabolism, immune function, and inflammatory homeostasis, with growing evidence highlighting its pivotal role in health and disease. Many phytochemicals exert their biological effects only after microbial biotransformation, while dietary components simultaneously shape the composition and metabolic activity of the gut microbiota. This bidirectional relationship has stimulated the development of next-generation microbiome-based nutraceuticals, including precision probiotics, synbiotics, postbiotics, and personalized dietary formulations designed to optimize individual health outcomes (10). Future nutraceutical strategies are expected to combine specific bioactive compounds with targeted modulation of the gut microbiome, providing more personalized and effective approaches to disease prevention and health promotion.

Despite these remarkable technological advances, several important scientific and regulatory challenges remain. For many commercially available nutraceuticals, clinical evidence remains insufficient to support broad therapeutic claims. Furthermore, substantial variability in plant species, geographical origin, cultivation conditions, harvesting practices, extraction procedures, manufacturing processes, and analytical methodologies often compromises product consistency and reproducibility across studies. Addressing these challenges requires rigorous standardization of herbal extracts using validated chemical markers, comprehensive pharmacokinetic and pharmacodynamic evaluation, implementation of quality-by-design (QbD) manufacturing principles, and well-designed, adequately powered randomized controlled clinical trials to translate promising preclinical findings into reliable clinical evidence (11). Harmonization of international regulatory frameworks is equally important to ensure product quality, safety, efficacy, and consumer confidence.

Sustainability has also become a major driving force in the future development of nutraceuticals.

Environmentally friendly extraction technologies, including supercritical fluid extraction, ultrasound-assisted extraction, microwave-assisted extraction, and natural deep eutectic solvents, are increasingly replacing conventional solvent-intensive methods. At the same time, agricultural by-products, food-processing waste, marine biomass, and underused botanical resources are emerging as sustainable sources of high-value bioactive compounds. These green technologies not only reduce the environmental footprint of nutraceutical production but also support the circular bioeconomy while creating new opportunities for pharmaceutical and nutritional innovation.

Ultimately, the future of nutraceuticals will depend not only on the discovery of new bioactive compounds but also on the successful integration of multidisciplinary technologies capable of converting these molecules into safe, effective, and clinically validated interventions. The convergence of natural product chemistry, advanced pharmaceutical technologies, nanotechnology, AI, systems biology, precision nutrition, and precision medicine is creating unprecedented opportunities for the development of next-generation nutraceuticals supported by robust scientific evidence. Continued collaboration among researchers in pharmaceutical sciences, nutrition, biotechnology, computational biology, and clinical medicine will be essential to move the field beyond traditional supplementation toward truly personalized, evidence-based preventive healthcare.

Footnotes

AI Use Disclosure: The authors declare that no generative AI tools were used in the creation of this article.

Authors' Contribution: The author conducted all aspects of the study.

Conflict of Interests Statement: The authors do not declare any conflicts of interests for this study.

Funding/Support: No funding was received for this study.

References

1. El Oirdi M. Harnessing the power of polyphenols: A new frontier in disease prevention and therapy. *Pharmaceuticals (Basel)*. 2024;**17**(6):692. [PubMed ID: 38931359]. [PubMed Central ID: PMC11206774]. https://doi.org/10.3390/ph17060692.
2. Xavier JR, Sanjay BS, Gupta D, Mehta S, Chauhan OP. Bioactive compounds of foods: Phytochemicals and peptides. *Food Humanity*. 2024;**3**. 100354. https://doi.org/10.1016/j.foohum.2024.100354.
3. Yang Y, Ling W. Health benefits and future research of phytochemicals: A literature review. *J Nutr*. 2025;**155**(1):87-101. [PubMed ID: 39536969]. https://doi.org/10.1016/j.tjnut.2024.11.007.
4. McClements DJ. Delivery by design (DbD): A standardized approach to the development of efficacious nanoparticle- and microparticle-based delivery systems. *Compr Rev Food Sci Food Saf*. 2018;**17**(1):200-219. [PubMed ID: 33350064]. https://doi.org/10.1111/1541-4337.12313.
5. Zhang J, Wang ZW, Mi Q. Colloidal delivery systems in foods: A general comparison with oral drug delivery. *LWT Food Sci Technol*. 2011;**44**(9):1958-1964. https://doi.org/10.1016/j.lwt.2011.05.021.
6. Mousavipour N, Babaei S, Moghimipour E, Moosavi-Nasab M, Ceylan Z. A novel perspective with characterized nanoliposomes: Limitation of lipid oxidation in fish oil. *LWT Food Sci Technol*. 2021;**152**. 112387. https://doi.org/10.1016/j.lwt.2021.112387.
7. Ordovas JM, Ferguson LR, Tai ES, Mathers JC. Personalized nutrition and health. *BMJ*. 2018;**361**:k2173. [PubMed ID: 29898881]. [PubMed Central ID: PMC6081996]. https://doi.org/10.1136/bmj.k2173.
8. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. *BMJ*. 2018;**361**:k2179. [PubMed ID: 29899036]. [PubMed Central ID: PMC6000740]. https://doi.org/10.1136/bmj.k2179.
9. Mullowney MW, Duncan KR, Elsayed SS, Garg N, van der Hooft JJJ, Martin NI, et al. Counting on AI for drug discovery. *Nat Rev Drug Discov*. 2024;**23**(2):87-109. [PubMed ID: 37697042]. [PubMed Central ID: PMC13118512]. https://doi.org/10.1038/s41573-023-00774-7.
10. Marco ML, Sanders ME, Gänzle M, Arrieta MC, Cotter PD, De Vuyst L, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods. *Nat Rev Gastroenterol Hepatol*. 2021;**18**(3):196-208. [PubMed ID: 33398112]. [PubMed Central ID: PMC7925329]. https://doi.org/10.1038/s41575-020-00390-5.
11. Espín JC, García-Conesa MT, Tomás-Barberán FA. Nutraceuticals: Facts and fiction. *Phytochemistry*. 2007;**68**(22 - 24):2986-3008. [PubMed ID: 17976666]. https://doi.org/10.1016/j.phytochem.2007.09.014.